1-3 of 3
Richard T. Penson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)

Krishnansu S. Tewari, Michael W. Sill, Bradley J. Monk, Richard T. Penson, David H. Moore, Heather A. Lankes, Lois M. Ramondetta, Lisa M. Landrum, Leslie M. Randall, Ana Oaknin, Mario M. Leitao, Eric L. Eisenhauer, Paul DiSilvestro, Linda Van Le, Michael L. Pearl, James J. Burke, Ritu Salani, Debra L. Richardson, Helen E. Michael, David W. Kindelberger, Michael J. Birrer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (11): 2363–2370.
https://doi.org/10.1158/1535-7163.MCT-20-0276
Published: 03 November 2020
View article titled, Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)
Open the PDF for Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062) in another window
Includes: Supplementary data
Journal Articles

Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer

Joyce F Liu, Su-Chun Cheng, Robert M Wenham, Andrea E Wahner Hendrickson, Deborah K Armstrong, Nancy Chan, David E Cohn, Jung-Min Lee, Richard T Penson, Mihaela Cristea, James Abbruzzese, Koji Matsuo, Alexander B Olawaiye, Jennifer Curtis, Geoffrey Shapiro, Ursula A Matulonis, Elise Kohn, Percy Ivy, Elizabeth M Swisher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A074.
https://doi.org/10.1158/1535-7163.TARG-19-A074
Published: 01 December 2019
View article titled, Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer
Journal Articles

Abstract C095: Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC)

Denise Uyar, Russell J Schilder, R Wendel Naumann, Fadi S Braiteh, Erika Hamilton, Sami Diab, John Moroney, Richard T Penson, Jennifer Smith, Cristina Abrahams, Michael Palumbo, Venita DeAlmeida, Shannon Matheny, Arturo Molina
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C095.
https://doi.org/10.1158/1535-7163.TARG-19-C095
Published: 01 December 2019
View article titled, Abstract C095: Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC)